Hybridoma technology

                          Hybridoma technology is a technology of forming hybrid cell lines (called Hybridoma) by fusing a specific antibody-producing B cell with a myeloma (B cell cancer) cell that is selected for its ability to grow in tissue culture and for an absence of antibody chain synthesis. The antibodies produced by the hybridoma are all of a single specificity and are therefore monoclonal antibodies (in contrast to polyclonal antibodies). The production of monoclonal antibodies was invented by Cesar Milstein, Georges J. F. Köhler and Niels Kaj Jerne in 1975.

The use of monoclonal antibodies is numerous and includes the prevention, diagnosis, and treatment of disease. For example, monoclonal antibodies can distinguish subsets of B cells and T cells, which is helpful in identifying different types of leukemia.

Monoclonal antibodies (mAb or moAb) are monospecific antibodies that are the same because they are made by one type of immune cell which are all clones of a unique parent cell. Given almost any substance, it is possible to create monoclonal antibodies that specifically bind to that substance; they can then serve to detect or purify that substance.

 Courtesy : Anusha Thampi V.V (SCT College of Engineering , TVM)

  Download :     Full Report (.doc)